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COST EFFECTIVENES OF THE PHARMACOLOGIC TREATMENT OF IRRITABLE
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1Universidad Nacional Autónoma de México, México City, Mexico, 2Instituto Mexicano del Seguro
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OBJECTIVES: Irritable Bowel Syndrome (IBS) is a chronic and relapsing sickness of
high economic impact on society and patients’ life quality. The purpose of this
study is to estimate the cost-effectiveness of treatment with otilonium bromide
(OB) compared with pinaverium bromide (PB) and hyoscine butilbromide (HB) in
the treatment of abdominal pain in patients with IBS from an institutional
perspective. METHODS: A cost-effectiveness analysis was developed using a
Markovmodeling approach: Themodel simulates cost and effectiveness outcomes
in a 6 month period for treatment of IBS with OB (40mg every 8 hrs); PB (10-20mg
every 8 hrs); and HB (50mg every 8 hrs). Three health conditions were considered
(“symptom control”, “continuing symptom profile” and “relapse”) with a 7-day
cycles. Effectiveness measures: clinic success rate and symptomless time. The
probabilities of transition were estimated from international random clinical.
Costs and resource use were collected from hospital records related to patients
with IBS at IMSS in 2010 (n150). The probabilistic sensitivity analysis was ob-
tained through a second-order Monte Carlo simulation RESULTS: The greatest
effectiveness of clinic improvement was shown by patients treated with OB (76%)
followed by those of PB (72%) andHB (66%). The greatest effectiveness in symptom-
less conditions was shown by OB (18 weeks) followed PB (17 weeks) and HB (15
weeks). Thus,mean cost per patientwere lowerwithOB (US$ 505.22) followed by PB
(US$530.74) and HB (US$642.71). Regarding the ICER, OB resulted the dominant
therapy. Acceptability curves showed OB as the most cost-effective therapy in
100% independently of IMSS willingness to pay. CONCLUSIONS: In Mexico, OB
represents the best cost-effective alternative since it offers greater control and
more symptomless weeks in patients with IBS. These results should be taken into
account by Mexican decision makers.
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OBJECTIVES: To compare all-cause resource utilization and health care costs be-
tween patients with diverticular disease (DD) and matched controls. METHODS:
Medical and pharmacy claims data from the Ingenix IMPACT Managed Care data-
basewere analyzed (2005–2008,40 health plans, all geographic regionswithin the
US represented). Patients with DDwere defined as those with primary diagnosis of
colonic diverticulitis (1 claim) followed by acute antibiotic treatment within 3
days of diagnosis (n36,636); first diverticulitis claim defined study index date.
Controls from the same database werematched 2:1 based on age, gender, and plan
enrollment dates (n73,272); the index date was the date of their respectivematch
from the DD group. Study eligibility required plan enrollment for 6 months pre-
index and12months post-index. Outcomeswere evaluated over 12months post-
index. Generalized linear models and negative binomial regression models were
used to estimate resource utilization and health care costs. Costs were adjusted to
2009 dollars. RESULTS: Rates of resource utilization and health care costs were
significantly higher for DD patients than for controls: hospitalization, ER visits, and
office visits were 8-fold (Incidence Rate Ratio [IRR]8.1), 4-fold (IRR3.7), and 2-fold
(IRR2.3) higher, respectively, than in controls; all P0.0001. Due to higher resource
utilization, adjustedmean total annual all-cause costs were substantially higher in
DD patients than controls ($16,933 vs. $7,028; P0.0001). The major drivers for the
cost difference were hospitalizations ($6,554 vs. $1,374), ER visits ($1,022 vs. $120),
outpatient/ancillary costs ($4,289 vs. $2,168), and office visits ($2,280 vs. $1,420); all
P0.0001. CONCLUSIONS: The economic burden of patients with DD is significant,
with substantial costs occurring in cost sectors such as hospitalization, ER, and
office visits. Interventions are needed to reduce diverticulitis occurrences and po-
tentially decrease the costs associated with hospitalization, ER visits, and outpa-
tient/ancillary services. Supported by funding from Shire Development Inc.
Gastrointestinal Disorders – Patient-Reported Outcomes & Preference-Based
Studies
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OBJECTIVES: Conventional antiviral therapy of treatment-naive genotype 1 hepa-
titis C virus (HCV)-infected patients consists of 48 weeks of pegylated interferon
and ribavirin combination. The purpose of this study was to document real-life
continuation rates to HCV therapy. METHODS: Commercially insured patients
with chronic HCV infection (ICD-9-codes 070.44,070.54, 070.70,070.71) with docu-
mented genotype 1 lab results were identified from a large US claims database
(Ingenix 2006–2009). Index date was treatment initiation of any combination of
(peg)interferon and/or ribavirin. Only genotype 1 patients with one year retrospec-
tive (pre-index) and prospective (post-index) available datawithout HCV treatment
in the retrospective yearwere included. Therapy discontinuationwas defined as an
observed refill gap of at least 56 days between two subsequent prescriptions. Time
to discontinuationwas analyzed using Kaplan-Meier andCox proportional hazards
regression. RESULTS: Of all patients with reported genotype, 82% (N332) were
genotype 1 patients. 95.2% initiated a combination of peginterferon and ribavirin.
Mean time on treatment was 261 days. 7.2% of all patients only had one prescrip-
tion without refill. For patients with at least one refill prescription, the hazard of
treatment discontinuation was constant over time. By week 24, 25.6% [95% CI 21.3–
30.7] had discontinued treatment, while 49.4% [43.9–54.6] of patients completed 48
weeks of therapy. Treatment discontinuations were not associated with age, gen-
der or co-morbidity. CONCLUSIONS:While a 48-week therapy for treatment-naive
genotype 1 patients is recommended with current standard of care to obtain sus-
tained viral response (SVR), we observed that in daily clinical practice 50.6% of the
patients discontinued therapy earlier. Low treatment continuation rates in real life
may result in lower SVR rates compared with what is observed in clinical trial
settings. Treatment completion ratesmay be higher with therapies allowing short-
ened treatment duration.
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METHODS IN TAIWANESE CHRONIC HEPATITIS B PATIENTS
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OBJECTIVES: The extent of difference regarding quality of life (QOL) according to
disease severity in chronic hepatitis B virus infection (CHB) has rarely been investi-
gated. The aim of the study was to explore the adaptation and appropriateness of
different utilitymeasures of QOL in Taiwanese CHBpatients.METHODS: Consecutive
adult CHB patientswho visited liver clinics at amedical center and a regional hospital
from July to December 2010were invited for interviews. Time-trade off (TTO), EuroQol
group 5-dimension (EQ-5D) questionnaire and 100-mm visual analogue scale (EQ-5D
VAS) were used to measure participations’ utility. The EQ-5D assessment was trans-
formed into EQ-5D index by using Japanese preference weight. Multivariate analysis
was used to evaluate the association between patients’ demography (age, marriage,
and employment status), Charlson comorbidity index and utility values. RESULTS: A
total of 120 patients (mean age48.0211.04 years, 85%male) were recruited, includ-
ing 20 patients of cirrhosis and 14 patients of hepatocellular carcinoma. The mean
utility andmeasurement success rates forEQ-5D index, EQ-5DVAS, andTTOwere0.83
 0.87 (98%), 0.89  0.14 (99%), and 0.65  0.29 (92%), respectively. The former two
utilities were significantly associated with employment status whilst TTO were sig-
nificantly associatedwithmarriage status. Therewas no difference in utility of EQ-5D
VAS, EQ-5D index and TTO between CHB patients (0.910.13, 0.770.14, 0.650.28),
CHB patients concomitantwith cirrhosis (0.86 0.16, 0.72 0.23, 0.69 0.32) and CHB
patients concomitant hepatocellular carcinoma (0.85  0.14, 0.71  0.20, 0.58  0.27).
CONCLUSIONS: EQ-5D questionnaire and EQ-5D VAS are feasible QOLmeasurement
inTaiwaneseCHBpatients. SinceTaiwanesepreferenceweight for transferring EQ-5D
assessment into EQ-5D index has not been established, further large-scale study is
needed to cross validate this measurement and explore the differences of QOL in
terms of disease severity.
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HEALTH-RELATED QUALITY OF LIFE IS LOWER FOR PATIENTS WITH DIURNAL
AND NOCTURNAL GERD SYMPTOMS
Goren A1, Gupta S2, Balu S3, Buchner D3
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OBJECTIVES: This study assessed whether health-related quality of life (HRQoL)
differed between respondents diagnosed with both diurnal and nocturnal gastro-
esophageal reflux disease (GERD) and those diagnosed with either type alone, or
non-diagnosed respondents.METHODS: Data were analyzed from Kantar Health’s
2010 National Health and Wellness Survey, a nationally representative dataset of
US adults (collected over three waves, January 7 to August 13). Outcome variables
were SF-12v2 mental and physical component summary (MCS and PCS) and SF6D
health utilities (measuring health status) scores. Lower scores indicate worse out-
comes. Analyses of covariance (ANCOVAs) predicted MCS, PCS, and SF6D from the
four GERD groups and a range of covariates. RESULTS: There were 75,000 respon-
dents: non-GERD (n68,593), diurnal (n710), nocturnal (n1,493), and diurnal-
and-nocturnal GERD (n4,204). Estimated means adjusted for the following cova-
riates (and others) at levels shown: gender (48% female); age (48.2); African
American (11%); Hispanic (6%); BMI: overweight (32%) and obese (33%); Charlson
comorbidity index, excluding ulcers (.397); and taking prescription for GERD (6%).
All groups exhibited significantly higher MCS scores than the diurnal-and-noctur-
nal GERD Group (MNon-GERD 48.6, SE 0.043;MDiurnal 47.5, SE 0.426;MNocturnal
47.4, SE  0.314; MDiurnal&Nocturnal  45.0, SE  0.249); higher PCS scores (MNon-GERD 
48.5, SE  0.038; MDiurnal  47.6, SE  0.377; MNocturnal  47.4, SE  0.278;
MDiurnal&Nocturnal  45.6, SE  0.220); and higher SF6D scores (MNon-GERD  0.752, SE 
0.001; MDiurnal  0.727, SE  0.005; MNocturnal  0.729, SE  0.004; MDiurnal&Nocturnal 
0.695, SE .003), all ps 0.001. CONCLUSIONS: Based on this analysis, respondents
with both diurnal-and-nocturnal GERD suffer poorer HRQoL than those with no
GERD, or only diurnal or nocturnal GERD. This suggests an unmet need to improve
medical care especially for those who have both diurnal and nocturnal GERD.
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IBS-C PATIENT SYMPTOM REPORTS: ANALYSIS OF EXPLORATORY OPEN-ENDED
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